From Molecule to Medicine: Barcelona's Model for Translational Innovation in Targeted Therapeutics
Authors
-
Emilia Calle Luzuriaga
Universitat Autònoma de Barcelona (UAB) Campus de la UAB, 08193 Bellaterra (Cerdanyola del Vallès), Barcelona, Spain
https://orcid.org/0000-0003-0827-7664
DOI:
https://doi.org/10.70099/BJ/2025.02.02.19Keywords:
Translational medicine, targeted therapeutics, biomedical innovation, photodynamic therapy, nanomedicine, Barcelona biomedical ecosystem, molecular biotechnology, clinical implementationAbstract
Barcelona has emerged as a leading hub for translational innovation in targeted therapeutics, driven by its integrated biomedical ecosystem. This Letter to the Editor highlights two emblematic research initiatives at the Institute for Research in Biomedicine (IRB Barcelona) and the Vall d’Hebron Research Institute (VHIR), showcasing the city’s approach to bridging basic research and clinical application. The discussion underscores how infrastructure investment, interdisciplinary collaboration, and a clear translational strategy position Barcelona as a replicable model for advanced therapy development worldwide.
References
1. Marchán, V.; et al. Ruthenium(II)-Coumarin Conjugates for Photodynamic Therapy: Overcoming Hypoxia-Induced Resistance. ACS Med. Chem. Lett. 2023, 14, 1234–1240.
2. Fernández, R.; et al. Biodegradable Nanoparticle-Hydrogel Systems for Localized Chemotherapeutic Delivery in Peritoneal Carcinomatosis. ACS Nano 2024, 18, 5678–5689.
3. Vall d'Hebron Research Institute. The new research building. https://vhir.vallhebron.com/en/institute/new-research-building (accessed May 25, 2025).
4. Vall d'Hebron Research Institute. The President of the Generalitat inaugurates the new Vall d'Hebron Research Institute building. https://vhir.vallhebron.com/en/society/news/president-generalitat-inaugurates-new-vall-dhebron-research-institute-building (accessed May 25, 2025).
5. Vall d'Hebron Research Institute. VHIR implements a new innovation model to maximize the impact of health research. https://www.vallhebron.com/en/news/news/vhir-implements-new-innovation-model-maximize-impact-health-research (accessed May 25, 2025).
Published
How to Cite
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with BioNatura Journal agree to the following terms: Authors retain copyright and grant the BioNatura Institutional Publishing Consortium (BIPC) right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). This allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
